We examine whether medical innovation can reinforce existing health disparities by disproportionately benefiting socioeconomically advantaged patients. The reason is that less advantaged patients often do not use new medications. This may be due to high costs of new drugs, but could also reflect...

We study the impact of a medical breakthrough (HAART) on domestic violence and illicit drug use among low-income women infected with HIV. To identify causal effects, we assume that variation in women's immune system health when HAART was introduced affected how strongly their experience of...

Health-maximizing and welfare-maximizing behaviors can be at odds, especially among disadvantaged groups, generating health disparities. We estimate a lifecycle model of medication and labor supply decisions using data on HIV-positive men. We evaluate an effective HIV treatment innovation that...

Many randomized experiments are plagued by attrition, even among subjects receiving more effective treatments. We estimate the subject's utility associated with the receipt of treatment, as revealed by dropout behavior, to evaluate treatment effects. Utility is a function of both "publicly...

Randomized experiments (REs) are viewed as the "gold standard" for the treatment evaluation, but many REs are plagued by attrition or non-compliance, even among subjects receiving the more effective treatment. This paper constructs an economic model of decision-making in which individuals make...